{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:14:46Z","timestamp":1707524086845},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,15]]},"DOI":"10.7759\/cureus.8641","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T17:30:07Z","timestamp":1592242207000},"source":"Crossref","is-referenced-by-count":0,"title":["An Advanced AIDS Patient With CD4 <20 and Plasmablastic Lymphoma Achieving Complete Response With the V-EPOCH Regimen"],"prefix":"10.7759","author":[{"given":"Blessie","family":"Nelson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelina","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Venkatesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21250","article-title":"HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases","volume":"83","author":"Castillo J","year":"2008","unstructured":"Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008, 83:804-809. 10.1002\/ajh.21250","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.2685","article-title":"Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy","volume":"99","author":"Wilson WH","year":"2002","unstructured":"Wilson WH, Grossbard ML, Pittaluga S, et al.. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002, 99:2685-2693. 10.1182\/blood.V99.8.2685","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0029","article-title":"NCCN guidelines insights: B-cell lymphomas, version 3.2019","volume":"17","author":"Zelenetz AD","year":"2019","unstructured":"Zelenetz AD,  Gordon LI, Abramson JS, et al.. NCCN guidelines insights: B-cell lymphomas, version 3.2019. J Natl Compr Canc Network. 2019, 17:650-661. 10.6004\/jnccn.2019.0029","journal-title":"J Natl Compr Canc Network"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","author":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","unstructured":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993, 329:987-994. 10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPV1I2QWKZKNJH","article-title":"Plasmablastic lymphoma and related disorders","volume":"136","author":"Hsi ED","year":"2011","unstructured":"Hsi ED, Lorsbach RB, Fend F, Dogan A. Plasmablastic lymphoma and related disorders. Am J Clin Pathol. 2011, 136:183-194. 10.1309\/AJCPV1I2QWKZKNJH","journal-title":"Am J Clin Pathol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo E","year":"2008","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2008, 117:5019-5032. 10.1182\/blood-2011-01-293050","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i33.11894","article-title":"Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature review","volume":"20","author":"Luria L","year":"2014","unstructured":"Luria L, Nguyen J, Zhou J, et al.. Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature review. World J Gastroenterol. 2014, 20:11894-11903.  10.3748\/wjg.v20.i33.11894","journal-title":"World J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25278","article-title":"Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma","volume":"116","author":"Abramson JS","year":"2010","unstructured":"Abramson JS, Hellmann M, Barnes JA, et al.. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010, 116:4283-4290. 10.1002\/cncr.25278","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24518","article-title":"Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma","volume":"115","author":"Ribrag V","year":"2009","unstructured":"Ribrag V, Gisselbrecht C, Haioun C. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma. Cancer. 2009, 115:4540-4546. 10.1002\/cncr.24518","journal-title":"Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3435-1","article-title":"The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis","volume":"97","author":"Lin Z","year":"2018","unstructured":"Lin Z, Chen X, Zhou Y, et al.. The role of bortezomib in newly diagnosed diffuse large B cell lymphoma: a meta-analysis. Ann Hematol. 2018, 97:2137-2144. 10.1007\/s00277-018-3435-1","journal-title":"Ann Hematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.12.1861","article-title":"Constitutive nuclear factor kappa B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells","volume":"194","author":"Davis RE","year":"2001","unstructured":"Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappa B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001, 194:1861-1874. 10.1084\/jem.194.12.1861","journal-title":"J Exp Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13300","article-title":"Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma","volume":"169","author":"Castillo JJ","year":"2015","unstructured":"Castillo JJ, Reagan JL, Sikov WM, Staudt LM. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015, 169:352-355. 10.1111\/bjh.13300","journal-title":"Br J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2601-6","article-title":"Infusional dose-adjusted EPOCH plus bortezomib for the treatment of plasmablastic lymphoma","volume":"95","author":"Fedele PL","year":"2016","unstructured":"Fedele PL, Gregory GP, Gilbertson M, Shortt J, Kumar B, Opat S, Grigoriadis G. Infusional dose-adjusted EPOCH plus bortezomib for the treatment of plasmablastic lymphoma. Ann Hematol. 2016, 95:667-668. 10.1007\/s00277-016-2601-6","journal-title":"Ann Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403460","article-title":"Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas","volume":"18","author":"An J","year":"2004","unstructured":"An J, Sun Y, Fisher M, Rettig M. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas. Leukemia. 2004, 18:1699-1704. 10.1038\/sj.leu.2403460","journal-title":"Leukemia"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1002985107","article-title":"Ef\ufb01cacy of bortezomib in a direct xenograft model of primary effusion lymphoma","volume":"107","author":"Sarosiek KA","year":"2010","unstructured":"Sarosiek KA, Cavallin LE, Bhatt S, et al.. Ef\ufb01cacy of bortezomib in a direct xenograft model of primary effusion lymphoma. Proc Natl Acad Sci USA. 2010, 107:13069-13074. 10.1073\/pnas.1002985107","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential ef\ufb01cacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy K","year":"2009","unstructured":"Dunleavy K, Pittaluga S, Czuczman MS, et al.. Differential ef\ufb01cacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009, 113:6069-6076. 10.1182\/blood-2009-01-199679","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15156","article-title":"Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma","volume":"184","author":"Castillo JJ","year":"2019","unstructured":"Castillo JJ, Guerrero-Garcia T, Baldini F, et al.. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol. 2019, 184:634-696. 10.1111\/bjh.15156","journal-title":"Br J Haematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/32600-an-advanced-aids-patient-with-cd4-20-and-plasmablastic-lymphoma-achieving-complete-response-with-the-v-epoch-regimen","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:22:55Z","timestamp":1707506575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/32600-an-advanced-aids-patient-with-cd4-20-and-plasmablastic-lymphoma-achieving-complete-response-with-the-v-epoch-regimen"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,15]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.8641","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,15]]}}}